血红蛋白类氧载体在肾移植中的应用前景  

Application prospect of hemoglobin-based oxygen carrier in kidney transplantation

作　　者：王欢 周文涛 刘嘉馨 王红 Wang Huan;Zhou Wentao;Liu Jiaxin;Wang Hong(Institute of Blood Transfusion,Chinese Academy of Medical Sciences,Chengdu 610052,China)

机构地区：[1]中国医学科学院输血研究所,成都610052

出　　处：《器官移植》2021年第6期754-760,共7页Organ Transplantation

基　　金：四川省科技计划项目(2021YJ0122)。

摘　　要：高质量的供器官对于移植成功至关重要,但随着肾衰竭患者的增多,标准供者已无法满足现阶段的移植需求,边缘供肾开始广泛应用于临床,这也对现有供肾保存方法提出了挑战。缺血-再灌注损伤(IRI)是影响肾移植术后早期移植物功能的重要因素之一,并且对移植物的长期存活产生有害影响。现有研究发现,血红蛋白类氧载体(HBOC)能够减轻肾移植过程中的IRI,有效改善供肾保存质量,延长供肾保存时间。本文综述了HBOC在肾移植中的研究进展,以期为改善供肾保存方法、提高供肾质量、改善受者预后提供参考。High-quality donor organs is of significance for the success of organ transplantation.However,standard donors fail to meet the requirements of kidney transplantation due to the increasing quantity of patients with kidney failure.Marginal donor kidneys have been widely applied in clinical practice,which also poses challenges to the existing preservation methods of donor kidneys.Ischemia-reperfusion injury(IRI)is one of the critical factors affecting the early graft function after kidney transplantation.In addition,it exerts harmful effect upon the long-term survival of the graft.Current studies have demonstrated that hemoglobin-based oxygen carrier(HBOC)may reduce the IRI during kidney transplantation,effectively improve the preservation quality and prolong the preservation time of donor kidney.In this article,the research progress on HBOC in kidney transplantation was reviewed,aiming to provide reference for modifying the preservation method of donor kidney,improve the quality of donor kidney and enhance clinical prognosis of the recipients.

关 键 词：肾移植 供肾保存 缺血-再灌注损伤(IRI) 血红蛋白类氧载体(HBOC) 低温机械灌注(HMP) 控制性携氧复温(COR) 全氟碳化合物(PFC) 缺氧诱导因子(HIF) 

分 类 号：R617[医药卫生—外科学] R331.141[医药卫生—临床医学]